216eP MegaMOST - A multicenter, open-label, molecularly selected bayesian phase II platform trial in advanced or metastatic solid tumors: Final analysis of the trametinib cohort — Olivier Trédan (2025)

Article2020

BET inhibitor molibresib for the treatment of advanced solid tumors: Final results from an open-label phase I/II study.

Sophie Cousin, Jean Yves Blay, Irene García, Johann S. de Bono, Christophe Le Tourneau, Víctor Moreno, José Trigo, Christine L. Hann, Arun Azad, Seock‐Ah Im, Geraldine Ferron‐Brady, Antara Datta, Yuehui Wu, Thierry Horner, Brandon E. Kremer, Arindam Dhar, Peter J. O’Dwyer, Geoffrey I. Shapiro, Sarina A. Piha‐Paul

Article2022

Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study

Funda Meric‐Bernstam, Randy F. Sweis, Stefan Kasper, Omid Hamid, Shailender Bhatia, Reinhard Dummer, Agostina Stradella, Georgina V. Long, Anna Spreafico, Toshio Shimizu, Neeltje Steeghs, Jason J. Luke, Sarah M. McWhirter, Thomas Müller, Nitya Nair, Nancy Lewis, Xinhui Chen, Andrew Bean, Lisa Kattenhorn, Marc R. Pelletier, Shahneen Sandhu

Preprint2023

Data from Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study

Randy F. Sweis, Stefan Kasper, Omid Hamid, Shailender Bhatia, Reinhard Dummer, Agostina Stradella, Georgina V. Long, Anna Spreafico, Toshio Shimizu, Neeltje Steeghs, Jason J. Luke, Sarah M. McWhirter, Thomas Müller, Nitya Nair, Nancy Lewis, Xinhui Chen, Andrew Bean, Lisa Kattenhorn, Marc R. Pelletier, Shahneen Sandhu, Funda Meric‐Bernstam

Preprint2023

Data from Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study

Funda Meric‐Bernstam, Randy F. Sweis, Stefan Kasper, Omid Hamid, Shailender Bhatia, Reinhard Dummer, Agostina Stradella, Georgina V. Long, Anna Spreafico, Toshio Shimizu, Neeltje Steeghs, Jason J. Luke, Sarah M. McWhirter, Thomas Müller, Nitya Nair, Nancy Lewis, Xinhui Chen, Andrew Bean, Lisa Kattenhorn, Marc R. Pelletier, Shahneen Sandhu

Preprint2023

Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort

Olivier Trédan, Maud Toulmonde, Christophe Le Tourneau, Laure Montané, Antoîne Italiano, Isabelle Ray‐Coquard, Christelle de la Fouchardière, François Bertucci, Anthony Gonçalvès, Carlos Gomez‐Roca, Benoît You, Valéry Attignon, Sandrine Boyault, Philippe A. Cassier, Armelle Dufresne, Séverine Tabone‐Eglinger, Alain Viari, Emilie Sohier, Maud Kamal, Gwenaëlle Garin, Jean Yves Blay, David Pérol

216eP MegaMOST - A multicenter, open-label, molecularly selected bayesian phase II platform trial in advanced or metastatic solid tumors: Final analysis of the trametinib cohort

Discussion(0)

Related publications

BET inhibitor molibresib for the treatment of advanced solid tumors: Final results from an open-label phase I/II study.

Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study

Data from Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study

Data from Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study

Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort